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In diabetic retinopathy (DR), pericyte dropout from capillary walls is believed to cause the
breakdown of the blood-retina barrier (BRB), which subsequently leads to vision-
threatening retinal edema. While various proinflammatory cytokines and chemokines are
upregulated in eyes with DR, their distinct contributions to disease progression remain
elusive. Here, we evaluated roles of stromal cell–derived factor-1a (SDF-1a) and its
receptor CXCR4 in the BRB breakdown initiated by pericyte deficiency. After inhibition of
pericyte recruitment to developing retinal vessels in neonatal mice, endothelial cells (ECs)
upregulated the expression of SDF-1a. Administration of CXCR4 antagonists, or EC-
specific disruption of the CXCR4 gene, similarly restored the BRB integrity, even in the
absence of pericyte coverage. Furthermore, CXCR4 inhibition significantly decreased both
the expression levels of proinflammatory genes (P < 0.05) and the infiltration of
macrophages (P < 0.05) into pericyte-deficient retinas. Taken together, EC-derived SDF-1a
induced by pericyte deficiency exacerbated inflammation through CXCR4 in an autocrine or
paracrine manner and thereby induced macrophage infiltration and BRB breakdown. These
findings suggest that the SDF-1a/CXCR4 signaling pathway may be a potential therapeutic
target in DR.
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Introduction
Diabetic retinopathy (DR) is a leading cause of  vision loss in working-age populations. DR occurs in 
about 35% of  diabetic patients, with most of  its symptoms being ascribable to anatomical and functional 
abnormalities in retinal blood vessels (1). For instance, diabetic macular edema (DME) resulting from 
blood-retina barrier (BRB) breakdown and subsequent vascular hyperpermeability may impair central 
vision at any clinical stage of  DR (2). Since protein concentration of  VEGF is increased in eyes with DR 
(3), intravitreal injections of  anti-VEGF drugs have been globally employed for the treatment of  DME. 
While anti-VEGF drugs are beneficial for vision maintenance and improvement in DR patients, repeated 
injections are usually required owing to DME recurrence (4). Moreover, a considerable proportion of  
patients are refractory to anti-VEGF drugs, suggesting the presence of  a VEGF-independent signaling 
pathway being involved in at least some DME cases (5).
Various proinflammatory cytokines and chemokines are also upregulated in eyes with DR (6, 7). Among 
them is stromal cell–derived factor-1α (SDF-1α), also known as CXCL12. Intravitreal levels of SDF-1α are 
intimately correlated with the presence of DME (8). SDF-1α binds to G protein–coupled CXCR4, which is 
expressed in endothelial cells (ECs), immune cells, hematopoietic stem cells, and neurons (9–12). Pharma-
cologic and genetic manipulation studies demonstrate critical roles for SDF-1α/CXCR4 signaling in retinal 
In diabetic retinopathy (DR), pericyte dropout from capillary walls is believed to cause the 
breakdown of the blood-retina barrier (BRB), which subsequently leads to vision-threatening retinal 
edema. While various proinflammatory cytokines and chemokines are upregulated in eyes with 
DR, their distinct contributions to disease progression remain elusive. Here, we evaluated roles of 
stromal cell–derived factor-1α (SDF-1α) and its receptor CXCR4 in the BRB breakdown initiated by 
pericyte deficiency. After inhibition of pericyte recruitment to developing retinal vessels in neonatal 
mice, endothelial cells (ECs) upregulated the expression of SDF-1α. Administration of CXCR4 
antagonists, or EC-specific disruption of the CXCR4 gene, similarly restored the BRB integrity, even 
in the absence of pericyte coverage. Furthermore, CXCR4 inhibition significantly decreased both 
the expression levels of proinflammatory genes (P < 0.05) and the infiltration of macrophages 
(P < 0.05) into pericyte-deficient retinas. Taken together, EC-derived SDF-1α induced by pericyte 
deficiency exacerbated inflammation through CXCR4 in an autocrine or paracrine manner and 
thereby induced macrophage infiltration and BRB breakdown. These findings suggest that the SDF-
1α/CXCR4 signaling pathway may be a potential therapeutic target in DR.
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angiogenic processes, including vascular sprouting and artery formation (13). We previously reported the direct 
effects of endothelial SDF-1α/CXCR4 signaling on the modulation of vascular permeability and inflammation 
(14). However, specific roles of this signaling axis in the initiation and progression of DR remain elusive, pri-
marily because hyperglycemic animal models fail to fully reproduce the pathophysiology of DR.
Histological analyses of  human retinas imply that dropout of  pericytes from retinal capillary walls 
leads to BRB breakdown in DR (15). Consistent with this notion, pericyte depletion in developing mouse 
retinas through disruption of  PDGF/PDGFRβ signaling produces clinical features of  DR, such as retinal 
vascular tortuosity and dilation and retinal edema and hemorrhage (16–19). Notably, in developing retinal 
vessels, pericyte deficiency directly induces inflammatory responses in ECs and subsequent infiltration of  
macrophages (20). The infiltrating macrophages further inflame ECs by secreting propermeable and proin-
flammatory cytokines, including VEGF. This vessel-damaging loop between ECs and macrophages leads to 
irreversible BRB breakdown (20). Therefore, signaling molecules involved in EC-macrophage interactions 
in pericyte-deficient retinas may be potential novel targets to treat DR.
In the current study, we identified SDF-1α/CXCR4 signaling as a crucial exacerbating factor in the 
inflammatory loop between ECs and macrophages in BRB breakdown following pericyte deficiency. Our 
findings support the conclusion that blocking the SDF-1α/CXCR4 signaling pathway may have clinical 
implications in the management of  DR.
Results
Pericyte deficiency induced BRB breakdown that mimicked DR pathology. In mock-treated C57/BL6 P8 mice, 
nearly the entire retinal surface was covered by vessels composed of  isolectin B4–positive ECs (Supplemen-
tal Figure 1A, top left; supplemental material available online with this article; https://doi.org/10.1172/
jci.insight.120706DS1). The ECs were enveloped by desmin-positive pericytes at both the vascular front 
and plexus (Supplemental Figure 1A, bottom left).
As previously shown (20), single intraperitoneal injections of  anti-PDGFRβ antibody APB5 resulted 
in distorted, shortened, and dilated retinal vessels in P8 mice (Supplemental Figure 1A, top right, and 
Supplemental Figure 1B). The treatment almost completely inhibited the recruitment of  pericytes to the 
retinal vessels (Supplemental Figure 1A, bottom right). The APB5-induced pericyte deficiency increased 
the leakage of  the plasma-component fibrinogen outside the retinal vessels, indicating a BRB breakdown 
(Supplemental Figure 1C). In addition, F4/80-positive round-shaped macrophages were infiltrated in the 
APB5-treated retina (Supplemental Figure 1D).
SDF-1α expression increased in pericyte-deficient retinas. We evaluated Sdf1a mRNA expression in murine 
retinas. A previous report demonstrated that APB5-induced pericyte deficiency induced inflammatory 
responses in ECs of  retinal vessels in P5 mice and caused severe edema and hemorrhage in P10 retinas (20). 
Consistent with this, our treatment of  mice with APB5 significantly increased the Sdf1a retinal expression 
in P5, P7, and P9 mice (Figure 1A).
In situ hybridization of  P8 mouse retinas revealed broadly expressed Sdf1a in mock-treated animals, 
including collagen IV–positive ECs (Figure 1B, left, shown by white arrowheads). In APB5-treated mice, 
retinal Sdf1a expression in ECs was markedly increased (Figure 1B, right, shown by white arrowheads).
CXCR4 expressed in the endothelium of  pericyte-deficient retina. Previous reports showed that the SDF-1α 
receptor CXCR4 is expressed in endothelial tip cells and arterial ECs in retinas of  postnatal mice (13). 
Consistent with this report, flow cytometry analysis showed that 66% of  CD31+CD45– ECs expressed 
CXCR4 in mock-treated mice (Figure 1D). Treatment with APB5 resulted in CD11b+CD45hi macro-
phages (20) infiltrating the P8 retinas (Figure 1C). In retinas of  APB5-treated mice, approximately 80% of  
CD31+CD45– ECs expressed CXCR4 (Figure 1D), compared with about 8% of  the macrophages (Figure 
1C). In line with these results, in situ hybridization of  Cxcr4 in P8 mouse retinas revealed that Cxcr4 was 
mainly localized to collagen IV–positive ECs both in PBS- and APB5-treated mouse retinas (Supplemental 
Figure 2, shown by white arrowheads).
Endothelial CXCR4 deficiency ameliorated the BRB disruption. We evaluated the functional contribution 
of  endothelial CXCR4 using tamoxifen-inducible endothelial-specific CXCR4-deficient mice (CXCR4iΔEC). 
Retinas from noninduced Cre– and induced Cre+ mice were analyzed at P8. In mock-treated mice, endo-
thelial CXCR4 deficiency did not affect vascular/BRB formation and macrophage infiltration (Figure 2). 
APB5 treatment shortened, dilated, and distorted the retinal vessels of  the Cre– mice exhibiting a wild-type 
CXCR4 phenotype (Figure 2, A and B). It also disrupted the BRB (Figure 2, C and D) and resulted in 
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elevated macrophage infiltration into the retina (Figure 2, E and F). APB5 treatment of  induced Cre+ mice 
that had an endothelial-specific CXCR4-deficient phenotype and caused extension, narrowing, and reten-
tion of  the retinal vessels (Figure 2, A and B). Induced CXCR4 deficiency also significantly attenuated BRB 
breakdown (Figure 2, C and D) and macrophage infiltration (Figure 2, E and F).
CXCR4 inhibition abrogated the pericyte deficiency–induced BRB disruption. We assessed whether phar-
macological inhibition of  SDF-1α/CXCR4 signaling was beneficial against pericyte deficiency–induced 
BRB disruption. As shown in Figure 3, A and B, treatment of  mice with CXCR4 inhibitor AMD3100 or 
FC131 on P3, P5, and P7 ameliorated the APB5-induced vascular shortening (almost complete inhibition) 
and dilation (about 60% inhibition). These inhibitors also significantly protected the mice from BRB 
disruption (Figure 3, C and D; about 40% inhibition) and macrophage infiltration (Figure 3, E and F; 
about 65% inhibition).
In consideration and comparison of  potential therapeutic application, we intravitreally administrat-
ed AMD3100 (P5; 1 μg/eye) and/or VEGF Trap (current first-line drug against DR, P5; 2.5 μg/eye). 
Local treatment with AMD3100 showed beneficial effect against APB5-induced BRB breakdown, which 
was comparable to VEGF Trap (Figure 4, A–E). However, we could not observe a synergistic effect of  
AMD3100 and VEGF Trap in these protocols (Figure 4, A–E).
We further evaluated the effect of  pharmacological blocking of  CXCR4 on the advanced forms of  
pericyte depletion–induced BRB breakdown. As shown in the middle image of  Figure 4F, APB5 treatment 
Figure 1. SDF-1α/CXCR4 expression was observed in retinal ECs in APB5-treated mouse retina. (A) The effect of APB5 on 
Sdf1a mRNA expression in P5, P7, and P9 mouse retinas (n = 6). (B) Representative images of retina in situ hybridization 
of Sdf1a (purple) and collagen IV (brown) on P8. White arrowheads indicate a double-positive staining region of Sdf1a and 
collagen IV. Scale bar: 50 μm. (C) Representative images of P8 mouse flow cytometry. Pink circles in left 2 graphs indicate 
CD11b+CD45hi macrophages. Pink rectangles in right 2 graphs indicate CXCR4-positive macrophages. (D) Representative 
images of P8 mouse flow cytometry. Pink rectangles in left 2 graphs indicate CD31+CD45– ECs. Pink rectangles in 2 right 
graphs indicate CXCR4-positive ECs. Significantly different from the results in vehicle-treated mice at *P < 0.05, signifi-
cantly different from the results in vehicle-treated mice.
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induced severe edema and hemorrhage, resulting in retinal collapse. Intraperitoneal AMD3100 treatment 
once daily from P8 through P10 significantly attenuated both the edema and hemorrhaging (Figure 4, F 
and G), suggesting therapeutic potential for pharmaceutical blocking of  CXCR4.
Inhibition of  CXCR4 decreased CCL2, ICAM-1, and E selectin mRNA expression. Macrophage infiltration is 
both a causative and an exacerbating factor of  BRB breakdown in the absence of  pericytes (20). Consistent-
ly, depletion of  macrophages by clodronate liposome (7 mg/ml, i.p., P4 and P5) in APB5-treated mouse 
Figure 2. Endothelial CXCR4 deficiency 
ameliorated the disruption of BRB. (A) 
Representative images of retina immunos-
taining of isolectin B4 (red) on P8. Scale 
bar: 500 μm (top); 100 μm (bottom). (B) 
The effect of endothelial CXCR4 deficiency 
(Cre+) on PBS- or APB5-treated retinal radius 
and vessel diameter on P8 (n = 5–6). (C) 
Representative images of retina immunos-
taining of isolectin B4 (red) and fibrinogen 
(green) on P8. Scale bar: 100 μm. (D) The 
effect of endothelial CXCR4 deficiency (Cre+) 
on PBS- or APB5-treated retinal fibrinogen 
intensity on P8 (n = 5–6). (E) Representative 
images of retina immunostaining of isolectin 
B4 (red) and F4/80 (green) on P8. Scale bar: 
100 μm. (F) The effect of endothelial CXCR4 
deficiency (Cre+) on PBS- or APB5-treated 
retinal F4/80-positive cells on P8 (n = 5–6). 
Significantly different from the results in 
Cre– mice at *P < 0.05, significantly different 
from the results in Cre– mice.
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Figure 3. CXCR4 inhibition abrogated the progression of APB5-induced BRB breakdown and macrophage infiltration. (A) Representative images 
of retina immunostaining of isolectin B4 (red) on P8. Scale bar: 500 μm (top); 50 μm (bottom). (B) The effect of AMD3100 (AMD) or FC131 (FC) on 
APB5-treated retinal radius and vessel diameter on P8 (n = 6–10). (C) Representative images of retina immunostaining of isolectin B4 (red) and 
fibrinogen (green) on P8. Scale bar: 100 μm (top); 30 μm (bottom). (D) The effect of AMD3100 or FC131 on APB5-treated retinal fibrinogen intensity 
on P8 (n = 6–10). (E) Representative images of retina immunostaining of isolectin B4 (red) and F4/80 (green) on P8. Scale bar: 100 μm (top); 30 μm 
(bottom). (F) The effect of AMD3100 or FC131 on APB5-treated retinal F4/80-positive cells on P8 (n = 6–10). Significantly different from the results 
in PBS- or APB5-treated mice at *P < 0.05, significantly different from the results in PBS-treated mice. #P < 0.05, significantly different from the 
results in APB5-treated mice.
6insight.jci.org   https://doi.org/10.1172/jci.insight.120706
R E S E A R C H  A R T I C L E
retinas almost completely rescued its vascular defects and BRB breakdown (Supplemental Figure 3, A–C). 
Therefore, we examined the effects of  a CXCR4 block on mRNA expression of  macrophage chemoattrac-
tant and adhesion molecules in APB5-treated retinas. As shown in Figure 5, APB5 treatment increased 
mRNA expression of  macrophage chemoattractants CCL2 and CCL7 in mouse retinas but not CCL12 
or CCL20 (Figure 5A). APB5 treatment also increased the expression of  endothelial adhesion molecules 
ICAM-1, VCAM-1, and E selectin (Figure 5B). Pretreatment with AMD3100 significantly attenuated the 
increase in mRNA levels of  CCL2, ICAM-1, and E selectin (Figure 5). CXCR4 inhibition may attenuate 
the infiltration of  macrophages, at least partially, through these molecules.
Figure 4. Local CXCR4 inhibition abrogated the APB5-induced pathologies comparably to VEGF Trap. (A) Representative images of retina immu-
nostaining of isolectin B4 (red) and fibrinogen (green) on P8. Scale bar: 100 μm. (B) The effect of AMD3100 (AMD) and/or VEGF Trap on APB5-treated 
retinal radius and vessel diameter on P8 (n = 5–8). (C) The effect of AMD3100 and/or VEGF Trap on APB5-treated retinal fibrinogen intensity on P8 (n = 
5–8). (D) Representative images of retina immunostaining of isolectin B4 (red) and F4/80 (green) on P8. Scale bar: 100 μm. (E) The effect of AMD3100 
and/or VEGF Trap on APB5-treated retinal F4/80-positive cells on P8 (n = 5–8). (F) Representative images of P11 mouse retina. (G) Retina grading 
scores of APB5- or APB5 and AMD3100–treated P11 mice (n = 6). Significantly different from the results in PBS- or APB5-treated mice at *P < 0.05, 
significantly different from the results in PBS-treated mice. #P < 0.05, significantly different from the results in APB5-treated mice.
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Discussion
SDF-1α is immediately upregulated under hypoxic conditions through the transcription factor hypox-
ia-inducible factor–1α (HIF-1α) (21). Previous reports show that HIF-1α–dependent SDF-1α upregulation 
occurs in astrocytes and/or ECs in several diseases, such as stroke and multiple sclerosis (22). Pericyte 
depletion induced by a PDGFRβ block is likely to decrease the number of  perfused functional vessels and 
to cause hypoxia (20). This consequently induces SDF-1α expression, primarily in retinal ECs (Figure 1B).
We previously reported that APB5-induced pericyte depletion results in macrophage infiltration into peri-
vascular areas that express VEGF, placental growth factor, and TNF-α (20). This phenomenon leads to sustained 
inflammation and subsequent BRB breakdown (20). Other groups have shown that, in streptozotocin-induced 
hyperglycemia, macrophages infiltrating the retina produce TNF-α, leading to vascular disruption and hyperper-
meability (23, 24). Therefore, infiltrating macrophages play an important role in the progression of retinopathy.
Our current findings demonstrate that the endothelial-derived SDF-1α stimulated its receptor CXCR4, 
predominantly on ECs, and indirectly stimulated macrophage infiltration by inducing chemokine/adhe-
sion molecule expression. Thus, SDF-1α may be a novel exacerbating factor that stimulates a vessel-dam-
aging cycle between ECs and macrophages in retinopathy. SDF-1α might also have direct effect on ECs. 
We previously showed that SDF-1α/CXCR4 signal activation attenuated vascular permeability in croton 
oil–induced skin inflammation in mice ear (14). In contrast, other researchers showed the exacerbation 
of  dipeptidyl peptidase 4 induced vascular leakage in mice ear (25). Further study is required to reveal its 
direct effect on ECs in progression of  retinopathy.
Pharmacological block of  CXCR4 decreased the expression of  the macrophage chemoattractant CCL2 
and endothelial adhesion molecules ICAM-1 and E selectin. CXCR4 is a Gi-type G protein–coupled recep-
tor (26). There are several reports showing that the activation of  Gi receptors increases the expression 
of  these molecules in human and murine ECs via activation of  p38 MAPK, JNK, and NF-κB signaling 
pathways (27–29). These pathways may be involved in the SDF-1α/CXCR4-induced expression of  chemo-
attractant and adhesion molecules.
Anti-VEGF antibody has been widely used to treat DME (4). However, this therapy has several disad-
vantages in terms of  disease unresponsiveness and adverse effects, including degeneration of  choroidal ves-
sels and macular atrophy (30–33). In our pericyte-deficient model, SDF-1α expression levels were elevated 
Figure 5. Endothelial CXCR4 increased the expression of chemoattractant and adhesion molecule. (A) The effect of 
APB5 or APB5 and AMD3100 (AMD) on macrophage chemoattractant mRNA expressions in P8 mouse retina (n = 8). 
(B) The effect of APB5 or APB5 and AMD3100 (AMD) on endothelial adhesion molecule mRNA expression in P8 mouse 
retina (n = 8). Significantly different from the results in vehicle-treated mice at *P < 0.05, significantly different from 
the results in vehicle-treated mice. #P < 0.05, significantly different from the results in APB treated mice).
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as early as at P6, whereas macrophage infiltration increased at P6 (20). Thus, it seems likely that EC-derived 
SDF-1α initiates macrophage infiltration and amplifies the inflammatory loop between macrophages and 
ECs in the absence of  pericytes. Blocking the SDF-1α signal may be a beneficial alternative strategy for DR 
patients who have lost responsiveness to anti-VEGF therapy (34).
In the present study, we identified SDF-1α/CXCR4 signaling as an exacerbating factor in the pericyte 
depletion–induced BRB breakdown and suggest therapeutic potential through its inhibition. Since admin-
istration of  an anti-PDGFRβ antibody APB5 induced features characteristic of  human DR, we believe that 
this model may mimic sequential events following pericyte dropout in human DR and prove useful in the 
assessment of  therapeutic targets. It should be noted that we utilized postnatal retina angiogenesis, while 
human DR typically occurs at a relatively old age. Further studies are needed to evaluate the contribution 
and potential therapeutic application of  SDF-1α/CXCR4 signaling in human DR.
Methods
Mice. Wild-type C57BL/6 mice were purchased from Sankyo Labo Service and Japan SLC. Pdgfb-iCreERT2 
mice (35) were crossed with CXCR4flox/flox mice (36) to produce Pdgfb-iCreERT2/CXCR4flox/flox mice. Litter-
mates lacking the Pdgfb-iCreERT2 transgene (CXCR4flox/flox) were used as controls. Conditional endothelial 
Cxcr4 gene deficiency (CXCR4iΔEC) was induced by intraperitoneal daily injection of  150 μg 4-hydroxy-
tamoxifen (MilliporeSigma) in 50 μl peanut oil from P1 to P3.
Pericyte deficiency–induced BRB breakdown model. Rat anti-mouse PDGFRβ monoclonal antibody APB5 
(18) was intraperitoneally injected into P1 mice (40 μg in 40 μl PBS). CXCR4 inhibitor AMD3100 (Abcam) 
at 40 mg/kg or FC131 (37) at 30 mg/kg was intraperitoneally injected at P3, P5, and P7. The retinas were 
analyzed at P8. In other experiments, AMD3100 was injected intraperitoneally daily from P8 through P10, 
and the retinas were analyzed at P11. For localized treatment, 1 μg AMD3100 in 0.6 μl PBS and/or 2.5 μg 
VEGF Trap (aflibercept, Bayer Pharma) in 0.6 μl PBS were intravitreally injected at P5, and the retinas were 
analyzed at P8. Clodronate liposomes (7 mg/ml in 50 ul PBS, i.p., P4 and P5) were injected to deplete infil-
trating macrophages in mouse retinas. In all procedures, mock-treated littermate controls received injections 
of  vehicle only. The severity of  retinal edema and hemorrhage was graded at P11, as described previously 
(20). In brief, scores were defined as follows: grade 1, no hemorrhage and edema; grade 2, local hemorrhage 
and/or mild edema; grade 3, edema in up to one half  of  the retina; and grade 4, collapse of  the retina.
Morphological analysis. Following fixation of  P8 mouse eyes with 4% paraformaldehyde (PFA) in 
PBS for 20 minutes, the retinal cups were dissected and further fixed in 4% PFA in PBS for 10 minutes. 
The fixed retinas were blocked with 1% bovine serum albumin and 0.5% Triton X-100 in PBS for 2 
hours and then incubated overnight with primary antibody rabbit anti-mouse desmin (Abcam; 1:200), 
rabbit anti-human fibrinogen (Dako; 1:500), or rat anti-mouse F4/80 (Bio-Rad, Tokyo; 1:200). The 
retinas were then treated with Alexa Fluor 594–conjugated isolectin B4 (Thermo Fisher Scientific; 
1:200) and either secondary antibody Alexa Fluor 488 anti-rabbit antibody (Thermo Fisher Scientific; 
1:500) or secondary antibody Alexa Fluor 488 anti-rat antibody (Thermo Fisher Scientific; 1:500), as 
appropriate, for 2 hours in 1 mM CaCl2, 1 mM MgCl2, 1 mM MnCl2, and 1% Triton X-100 in PBS. 
Nuclei were labeled with DAPI (MilliporeSigma) at 1 μg/ml for 15 minutes. Fluorescent and confo-
cal microscopic images were captured using a Nikon Eclipse Ti microscope and C1 confocal system 
(Nikon). The images were analyzed with NIS-Elements D software (Nikon). The radii of  retinal vas-
cular networks were calculated using the distances from the optic nerve to the angiogenic front. The 
vessel diameters were calculated by averaging those for 3 arteries and veins per retina, approximately 
200–300 μm from the optic nerve head. Fibrinogen intensity was calculated measuring 20 random 
areas at the vascular front per retina. The number of  macrophages per area was estimated from counts 
in four 300 × 300–μm fields per retina.
Real-time PCR. Retinas were harvested at P5, P7, P8, and P9 from mice treated by intraperitoneal injec-
tion of  40–60 μg APB5 in 40 μl PBS or were mock treated with vehicle only at P1. Total RNA was extracted 
using TRI-Reagent (Molecular Research Center, Cincinnati, Ohio, USA) and the first strand of  cDNA was 
reverse transcribed using a random 9-mer primer (TOYOBO) and ReverTra Ace (TOYOBO), as directed by 
the manufacturers. The cDNA was amplified using Platinum SYBR Green qPCR SuperMix-UDG (Ther-
mo Fisher Scientific) and AriaMx Real-Time PCR System (Agilent Technologies). The mRNA expression 
levels were quantitated with the ΔCt method, using 18S rRNA or TBP mRNA levels as endogenous con-
trols. Primer sequences are shown in Supplemental Table 1.
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In situ hybridization. Sdf1a and Cxcr4 mRNA expression in whole-mount retinas was detected using digoxi-
genin-labeled (DIG-labeled) cRNA probes and alkaline phosphatase–conjugated (AP-conjugated) anti-DIG 
antibody (Roche) followed by NBT/BCIP staining (Roche), as previously described (38). After in situ hybrid-
ization, the retinas were immunostained with rabbit anti-type IV collagen antibody (Cosmo Bio) and bioti-
nylated by anti-rabbit antibody (VECTOR). The AP and DAB staining was assessed with an OPTIHOT-2 
microscope (Nikon) equipped with associated software (ACT-1C, Nikon).
Flow cytometry. Flow cytometry was conducted as previously described (39–41). P8 retinas were 
mechanically dissociated and enzymatically digested using 0.5 mg/ml collagenase D (MilliporeSigma) and 
750 U/ml DNase (MilliporeSigma) in Hanks’ balanced salt solution (MilliporeSigma) for 25 minutes. Ret-
inas were then forced through a 100-μm nylon mesh to obtain single-cell suspensions. Cells were labeled 
with fluorescence-conjugated antibodies for 30 minutes as follows: Alexa Fluor 488 anti-mouse CD45 (Bio-
legend), PE anti-mouse/human CD11b (Biolegend), PE anti-mouse CD31 (Biolegend), or Alexa Fluor 
647 anti-mouse CD184 (CXCR4). Viability staining solution 7-aminoactinomycin D (7-AAD; Biolegend) 
was applied for 5 minutes, and the analyses were conducted using a BD Accuri C6 Flow Cytometer (BD 
Biosciences). Following removal of  dead cells based on 7-AAD labeling, the doublet cells were excluded 
using forward scatter height (FSC-H) versus forward scatter width (FSC-W) gates. Further analyses were 
conducted using BD Accuri C6 Software (BD Biosciences).
Statistics. Data are shown as mean ± SEM. Statistical evaluation between 2 groups was conducted by 
Student’s t test (2 tailed, parametric) or Mann-Whitney’s U test (nonparametric). Statistical evaluation of  3 
groups was performed by 1-way ANOVA followed by Tukey’s test. A value of  P < 0.05 was considered to 
indicate statistically significant differences.
Study approval. Animal experiments were approved by the Institutional Animal Care and Use Com-
mittee of  The University of  Tokyo and the Animal Research Committee of  Nagoya City University and 
performed according to the Association for Research in Vision and Ophthalmology Statement for the Use 
of  Animals in Ophthalmic and Vision Research.
Author contributions
KO conducted experiments, acquired and provided data, and wrote the manuscript. KK, YF, NN, and ES 
conducted experiments and acquired and provided data. NF, TNH, YT, MF, and TN analyzed data and 
provided reagents. AU designed research studies, analyzed data, provided reagents, and wrote the manu-
script. TM designed research studies, analyzed data, and wrote the manuscript.
Acknowledgments
This work was supported by a Grant-in-Aid for Japan Society for the Promotion of  Science fellows (no. 
10795) to KO and by a Grant-in-Aid from the Japan Society for the Promotion of  Science (17H01509 and 
17H06252), the Charitable Trust Fund for Ophthalmic Research in Commemoration of  Santen Pharma-
ceutical’s Founder, the SENSHIN Medical Research Foundation, the Cardiovascular Research Fund, the 
Nakatomi Foundation, the Naito Foundation (to TM), and the NOVARTIS Foundation (Japan) for the 
Promotion of  Science.
Address correspondence to: Takahisa Murata, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan. Phone: 
81.3.5841.7247; Email: amurata@mail.ecc.u-tokyo.ac.jp.
 1. Yau JW, et al. Global prevalence and major risk factors of  diabetic retinopathy. Diabetes Care. 2012;35(3):556–564.
 2. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366(13):1227–1239.
 3. Aiello LP, et al. Vascular endothelial growth factor in ocular fluid of  patients with diabetic retinopathy and other retinal disor-
ders. N Engl J Med. 1994;331(22):1480–1487.
 4. Diabetic Retinopathy Clinical Research Network, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. 
N Engl J Med. 2015;372(13):1193–1203.
 5. Arevalo JF, et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina 
Study Group at 24 months. Ophthalmology. 2009;116(8):1488–1497.e1.
 6. Bromberg-White JL, Glazer L, Downer R, Furge K, Boguslawski E, Duesbery NS. Identification of  VEGF-independent cyto-
kines in proliferative diabetic retinopathy vitreous. Invest Ophthalmol Vis Sci. 2013;54(10):6472–6480.
 7. Dai Y, Wu Z, Wang F, Zhang Z, Yu M. Identification of  chemokines and growth factors in proliferative diabetic retinopathy 
vitreous. Biomed Res Int. 2014;2014:486386.
 8. Brooks HL, et al. Vitreous levels of  vascular endothelial growth factor and stromal-derived factor 1 in patients with dia-
1 0insight.jci.org   https://doi.org/10.1172/jci.insight.120706
R E S E A R C H  A R T I C L E
betic retinopathy and cystoid macular edema before and after intraocular injection of  triamcinolone. Arch Ophthalmol. 
2004;122(12):1801–1807.
 9. Chatterjee M, et al. Platelet-derived CXCL12 regulates monocyte function, survival, differentiation into macrophages and foam 
cells through differential involvement of  CXCR4-CXCR7. Cell Death Dis. 2015;6:e1989.
 10. Petit I, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol. 
2002;3(7):687–694.
 11. Pi X, Wu Y, Ferguson JE, Portbury AL, Patterson C. SDF-1alpha stimulates JNK3 activity via eNOS-dependent nitrosylation 
of  MKP7 to enhance endothelial migration. Proc Natl Acad Sci USA. 2009;106(14):5675–5680.
 12. Itoh T, et al. The relationship between SDF-1alpha/CXCR4 and neural stem cells appearing in damaged area after traumatic 
brain injury in rats. Neurol Res. 2009;31(1):90–102.
 13. Strasser GA, Kaminker JS, Tessier-Lavigne M. Microarray analysis of  retinal endothelial tip cells identifies CXCR4 as a media-
tor of  tip cell morphology and branching. Blood. 2010;115(24):5102–5110.
 14. Kobayashi K, et al. Stromal cell-derived factor-1α/C-X-C chemokine receptor type 4 axis promotes endothelial cell barrier integ-
rity via phosphoinositide 3-kinase and Rac1 activation. Arterioscler Thromb Vasc Biol. 2014;34(8):1716–1722.
 15. Cogan DG, Toussaint D, Kuwabara T. Retinal vascular patterns. IV. Diabetic retinopathy. Arch Ophthalmol. 1961;66:366–378.
 16. Klinghoffer RA, Mueting-Nelsen PF, Faerman A, Shani M, Soriano P. The two PDGF receptors maintain conserved signaling 
in vivo despite divergent embryological functions. Mol Cell. 2001;7(2):343–354.
 17. Enge M, et al. Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy. EMBO J. 
2002;21(16):4307–4316.
 18. Uemura A, et al. Recombinant angiopoietin-1 restores higher-order architecture of  growing blood vessels in mice in the absence 
of  mural cells. J Clin Invest. 2002;110(11):1619–1628.
 19. Lindblom P, et al. Endothelial PDGF-B retention is required for proper investment of  pericytes in the microvessel wall. Genes 
Dev. 2003;17(15):1835–1840.
 20. Ogura S, et al. Sustained inflammation after pericyte depletion induces irreversible blood-retina barrier breakdown. JCI Insight. 
2017;2(3):e90905.
 21. Ceradini DJ, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of  SDF-1. Nat Med. 
2004;10(8):858–864.
 22. Li M, Ransohoff  RM. Multiple roles of  chemokine CXCL12 in the central nervous system: a migration from immunology to 
neurobiology. Prog Neurobiol. 2008;84(2):116–131.
 23. Portillo JC, et al. CD40 in retinal Müller cells induces P2X7-dependent cytokine expression in macrophages/microglia in dia-
betic mice and development of  early experimental diabetic retinopathy. Diabetes. 2017;66(2):483–493.
 24. Rangasamy S, McGuire PG, Franco Nitta C, Monickaraj F, Oruganti SR, Das A. Chemokine mediated monocyte traf-
ficking into the retina: role of  inflammation in alteration of  the blood-retinal barrier in diabetic retinopathy. PLoS One. 
2014;9(10):e108508.
 25. Lee CS, et al. Dipeptidyl peptidase-4 inhibitor increases vascular leakage in retina through VE-cadherin phosphorylation. Sci 
Rep. 2016;6:29393.
 26. Murphy PM, et al. International union of  pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev. 
2000;52(1):145–176.
 27. Lee HY, et al. Sphingosylphosphorylcholine stimulates CCL2 production from human umbilical vein endothelial cells. J Immu-
nol. 2011;186(7):4347–4353.
 28. Dzenko KA, Song L, Ge S, Kuziel WA, Pachter JS. CCR2 expression by brain microvascular endothelial cells is critical for 
macrophage transendothelial migration in response to CCL2. Microvasc Res. 2005;70(1-2):53–64.
 29. Herlaar E, Brown Z. p38 MAPK signalling cascades in inflammatory disease. Mol Med Today. 1999;5(10):439–447.
 30. Simó R, Hernández C. Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence. Prog Retin Eye 
Res. 2015;48:160–180.
 31. Ford JA, Lois N, Royle P, Clar C, Shyangdan D, Waugh N. Current treatments in diabetic macular oedema: systematic review 
and meta-analysis. BMJ Open. 2013;3(3):e002269.
 32. Bolinger MT, Antonetti DA. Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy. Int J Mol Sci. 
2016;17(9):1498.
 33. Ehrlich R, Dan I, Deitch I, Axer-Siegel R, Mimouni K. The effectiveness of  intravitreal ranibizumab in patients with diabetic 
macular edema who have failed to respond to intravitreal bevacizumab. Ophthalmologica. 2016;235(3):133–136.
 34. Yang CS, Hung KC, Huang YM, Hsu WM. Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in the treat-
ment of  high-risk proliferative diabetic retinopathy. J Ocul Pharmacol Ther. 2013;29(6):550–555.
 35. Claxton S, Kostourou V, Jadeja S, Chambon P, Hodivala-Dilke K, Fruttiger M. Efficient, inducible Cre-recombinase activation 
in vascular endothelium. Genesis. 2008;46(2):74–80.
 36. Tokoyoda K, Egawa T, Sugiyama T, Choi BI, Nagasawa T. Cellular niches controlling B lymphocyte behavior within bone mar-
row during development. Immunity. 2004;20(6):707–718.
 37. Fujii N, et al. Molecular-size reduction of  a potent CXCR4-chemokine antagonist using orthogonal combination of  conforma-
tion- and sequence-based libraries. Angew Chem Int Ed Engl. 2003;42(28):3251–3253.
 38. Uemura A, Kusuhara S, Wiegand SJ, Yu RT, Nishikawa S. Tlx acts as a proangiogenic switch by regulating extracellular assem-
bly of  fibronectin matrices in retinal astrocytes. J Clin Invest. 2006;116(2):369–377.
 39. Dejda A, et al. Neuropilin-1 mediates myeloid cell chemoattraction and influences retinal neuroimmune crosstalk. J Clin Invest. 
2014;124(11):4807–4822.
 40. Kerr EC, Raveney BJ, Copland DA, Dick AD, Nicholson LB. Analysis of  retinal cellular infiltrate in experimental autoimmune 
uveoretinitis reveals multiple regulatory cell populations. J Autoimmun. 2008;31(4):354–361.
 41. Kusuhara S, et al. Arhgef15 promotes retinal angiogenesis by mediating VEGF-induced Cdc42 activation and potentiating RhoJ 
inactivation in endothelial cells. PLoS One. 2012;7(9):e45858.
